Regeneron launches radiopharma push with Telix in a potential $2.1B collaboration
Regeneron pays Telix $40 million upfront to co-develop four radiopharmaceutical programs for solid tumors, with an option to add four more. If milestones are met, Telix could earn up to $2.1 billion in biobucks, or opt for milestone-based payments under a cost-sharing model, with shared global commercialization and potential co-promotion. Regeneron will select targets from its antibody portfolio and may pair these agents with Libtayo; the deal also covers diagnostics, with Telix leading commercialization. The collaboration follows Telix’s recent radiopharma expansion and comes amid regulatory headwinds for Telix’s imaging assets.
